Two promising pharmaceutically targetable biomarkers for GBM include interleukin-13 receptor α chain variant 2 (IL-13RA2) [11] and the Eph receptor A2 [12–15]; together, these are overexpressed in over 90% of GBMs [16]. The gene discussed is EPHA2; the disease is glioblastoma.